Nationwide Fund Advisors raised its stake in Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) by 7.9% during the second quarter, Holdings Channel reports. The fund owned 101,448 shares of the specialty pharmaceutical company’s stock after buying an additional 7,469 shares during the period. Nationwide Fund Advisors owned 0.21% of Supernus Pharmaceuticals worth $2,066,000 as of its most recent SEC filing.
Other large investors have also added to or reduced their stakes in the company. Ameriprise Financial Inc. raised its stake in Supernus Pharmaceuticals by 17.3% in the second quarter. Ameriprise Financial Inc. now owns 912,740 shares of the specialty pharmaceutical company’s stock valued at $18,592,000 after buying an additional 134,544 shares during the last quarter. Scout Investments Inc. raised its stake in Supernus Pharmaceuticals by 4.8% in the second quarter. Scout Investments Inc. now owns 172,300 shares of the specialty pharmaceutical company’s stock valued at $3,510,000 after buying an additional 7,850 shares during the last quarter. Neuberger Berman Group LLC acquired a new stake in Supernus Pharmaceuticals during the second quarter valued at about $387,000. Lebenthal Lisanti Capital Growth LLC acquired a new stake in Supernus Pharmaceuticals during the second quarter valued at about $757,000. Finally, State Board of Administration of Florida Retirement System raised its stake in Supernus Pharmaceuticals by 15.3% in the second quarter. State Board of Administration of Florida Retirement System now owns 23,176 shares of the specialty pharmaceutical company’s stock valued at $472,000 after buying an additional 3,082 shares during the last quarter. 94.66% of the stock is owned by institutional investors.
Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) traded up 3.20% on Thursday, reaching $22.23. 288,355 shares of the company’s stock were exchanged. Supernus Pharmaceuticals Inc. has a 12 month low of $9.51 and a 12 month high of $26.84. The stock has a market capitalization of $1.10 billion, a PE ratio of 45.37 and a beta of 1.73. The firm has a 50 day moving average of $23.58 and a 200 day moving average of $20.23.
Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Tuesday, August 2nd. The specialty pharmaceutical company reported $0.18 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.13 by $0.05. Supernus Pharmaceuticals had a net margin of 14.94% and a return on equity of 20.99%. The business had revenue of $50.40 million for the quarter, compared to analyst estimates of $49.67 million. During the same quarter in the previous year, the firm posted $0.03 earnings per share. Supernus Pharmaceuticals’s revenue was up 43.6% compared to the same quarter last year. Equities analysts predict that Supernus Pharmaceuticals Inc. will post $0.68 earnings per share for the current fiscal year.
Several research firms have recently issued reports on SUPN. Zacks Investment Research raised shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $26.00 price objective for the company in a research report on Wednesday, October 5th. Jefferies Group reaffirmed a “buy” rating and set a $28.00 price target (up from $23.00) on shares of Supernus Pharmaceuticals in a report on Thursday, August 4th. Northland Securities lowered shares of Supernus Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $24.00 price target for the company. in a report on Monday, July 18th. Finally, Piper Jaffray Cos. lowered shares of Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and set a $23.00 price target for the company. in a report on Monday, July 18th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Supernus Pharmaceuticals presently has an average rating of “Buy” and an average price target of $25.25.
In related news, CFO Gregory S. Patrick sold 2,000 shares of the business’s stock in a transaction on Friday, September 16th. The shares were sold at an average price of $25.00, for a total transaction of $50,000.00. Following the transaction, the chief financial officer now owns 3,616 shares of the company’s stock, valued at $90,400. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 6.10% of the company’s stock.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR).
Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals Inc. (NASDAQ:SUPN).
Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.